Back to search results

5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder

Abroad (travel likely)RecruitingPHASE2

Conditions

Tobacco Use Disorder

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • University of Alabama at Birmingham, Birmingham, Alabama, United States

    Contact: Study coordinator (Seher Premani, M.P.H.) · spremani@uab.edu · 205-975-7721
    Contact: Study coordinator (Lindsey Owens, M.A.) · ltowens@uab.edu · 205-975-7721
    Contact: Principal Investigator (Peter Hendricks, Ph.D.)

  • Johns Hopkins University School of Medicine, Baltimore, Maryland, United States

  • New York University, New York, New York, United States

Study leads

  • Matthew Johnson, Ph.D

    Principal Investigator

    Johns Hopkins University

View source on ClinicalTrials.gov(opens in a new tab)